Preference for injectable over oral HIV pre|exposure prophylaxis in ...

Preference for injectable over oral HIV pre-exposure prophylaxis in ...

In summary, approximately 3 in 4 individuals engaging in PrEP services in outpatient care in Swaziland reported a preference for LAI over oral PrEP for ...

Preference for injectable over oral HIV pre-exposure prophylaxis in ...

Long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) may mitigate adherence challenges reported by young women in Southern ...

Preference for injectable over oral HIV pre-exposure... - AIDS

Whereas oral formulations of pre-exposure prophylaxis (PrEP) are efficacious in MSM, injecting drug users, and members of stable, discordant partnerships, ...

Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre ...

Fifty-five of 62 women who inject drugs (WWID) selected long-acting cabotegravir (CAB-LA) over oral PrEP, and 51/55 received a first injection.

Preference for injectable over oral HIV pre-exposure prophylaxis in ...

Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland. Siedner Mark J.; Hettema ...

Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre ...

Fifty-five of 62 women who inject drugs (WWID) selected long-acting cabotegravir (CAB-LA) over oral PrEP, and 51/55 received a first ...

Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre ...

HIV prevention; pre-exposure prophylaxis; women who inject drugs; long-acting injectable cabotegravir. Received 24 April 2024; editorial ...

Injectable Pre-Exposure Prophylaxis for HIV Prevention

Research from the United States and Australia on willingness to use long-acting PrEP has demonstrated that many GBQM are interested in using or ...

Full article: Perceptions of the attributes of new long-acting HIV pre ...

CAB-LA is an injectable ARV administered bi-monthly, intramuscularly, for HIV-negative people. It is also over 90% effective in preventing HIV infections ( ...

Preference for novel biomedical HIV pre-exposure prophylaxis ...

Results: Participants preferred methods were: HIV vaccine (34.7%), oral PrEP (25.7%), injectable PrEP (24.9%), PrEP implant (13.6%), and vaginal ...

Exploring preferences and decision-making about long-acting ...

Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (i.e., LAI-PrEP) was approved by the U.S. FDA in 2021.

Dynamic choice HIV prevention with cabotegravir long-acting ...

The intervention provided person-centred choice of oral pre-exposure prophylaxis (PrEP) or post-exposure HIV prophylaxis (PEP) or cabotegravir ...

Systematic review of the values and preferences regarding the use ...

Pre-exposure prophylaxis (PrEP) is an important HIV prevention option. Two randomized trials have provided efficacy evidence for long-acting ...

Injectable pre-exposure prophylaxis is better than oral form in ...

New UCLA-led research finds that long lasting injectable pre-exposure prophylaxis is superior to daily oral antiretroviral therapy in preventing HIV infection.

WHO recommends long-acting cabotegravir for HIV prevention

Long-acting injectable products have also been found to be acceptable and sometimes preferred in studies examining community PrEP preferences.

Predicted effects of the introduction of long-acting injectable ...

Pre-exposure prophylaxis (PrEP) has the potential to substantially reduce HIV incidence but studies done in the region on use of oral PrEP have ...

Clinical Guidance for PrEP | HIV Nexus - CDC

Required testing differs depending on recent antiretroviral PrEP or PEP (post-exposure prophylaxis) use. "Recent use" is defined as taking oral ...

Worth a shot: Injectable PrEP for HIV prevention - CATIE.ca

Since no safety concerns were identified in the studies, the US guidelines do not recommend an oral lead-in period before starting cabotegravir ...

HIV pre-exposure prophylaxis - UpToDate

Oral and injectable PrEP are both effective in reducing HIV transmission. The decision to use one strategy over the other depends upon ...

Guidelines on long-acting injectable cabotegravir for HIV prevention

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option ...